Maker of single-use medical devices for cardiovascular, endoscopy and interventional radiology procedures.
Maker of single-use medical devices for cardiovascular, endoscopy and interventional radiology procedures.
Sells disposable devices through its own sales force to hospitals, so revenue rises and falls with procedure counts. Procedure kits that bundle several of its products are one route to selling more per hospital. Founded in Utah in 1987, it has grown partly by buying small device businesses.
Moat: narrow (scale, switching costs). Broad catalog of single-use interventional devices with established hospital purchasing relationships.
Headquarters: South Jordan, Utah, USA · Founded: 1987 · Employees: 7,500
Size Merit Medical Systems (MMSI) is a United States Health Care company (Medical Specialties) with a market value of $5.15B, the 1159th largest of 3,085 United States companies the cockpit tracks. Shares closed at $85.93 on 18 Nov 2026.
Performance Over six months the shares gained 33.2%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 9.3% over the last twelve months (peer median +3.5%); the operating margin is 13.6% (peer median 14.6%).
Valuation It trades at 19.1× forward earnings against a peer median of 20.0× (9th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.8 points above its cost of capital (7.5% WACC).
Credit Merit Medical Systems has 1 bond outstanding ($748M).
Short interest Short interest is 6.7% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.61B | $1.51B | $1.35B | $1.25B | $1.15B |
| Revenue growth | — | +12% | +8% | +9% | — |
| Gross profit | $797M | $737M | $641M | $522M | $469M |
| EBITDA | $355M | $319M | $271M | $223M | $191M |
| Net income | $160M | $128M | $120M | $94.4M | $74.5M |
| Free cash flow | $204M | $216M | $186M | $111M | $69.3M |
| Capital expenditure | $73.2M | $84.8M | $38.0M | $36.7M | $48.2M |
| Total debt | $822M | $822M | $795M | $891M | $269M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Merit Medical Systems MMSI | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MMSI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.8% | +8.6% | 4th lowest of 21 |
| 6-month return | +33.2% | +23.4% | 8th highest of 21 |
| Distance from 52-week high | -9.4% | -14.6% | 10th highest of 21 |
| Revenue growth (TTM) | +9.3% | +3.5% | 9th highest of 21 |
| Operating margin | 13.6% | 14.6% | 9th lowest of 21 |
| Forward P/E | 19.1× | 20.0× | 9th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 12.6% | 10.0% | 8th most demanding of 17 |
| Growth delivered (Del g) | +9.5% | +7.8% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | +3.2 pp | +1.8 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | +0.8 pp | +2.5 pp | 9th lowest of 21 |
| EV / EBITDA | 15.4× | 13.9× | 7th most expensive of 15 |
| Net debt / EBITDA | 0.9× | 1.1× | 6th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
Merit Medical Systems has 1 bond outstanding with $748M face value.